Immunotherapy R&D for IBD

Both UC and CD are forms of inflammatory bowel disease (IBD). As an autoimmune disease, the inflammation has been understood as being ignited in principle by the innate immune system and then perpetuated by the adaptive immune system, thereby facilitating progression of disease. A virtually exponential growth in the understanding of the role of the immune system in the pathophysiology of IBD has paved the way for a multitude of several (immune) targeted therapies, from the innate to the adaptive immune system and from the targets connecting both immune systems, including anti-leukocyte trafficking agents – integrins and adhesion molecules.

Fig. 1. New drugs in IBD targeting innate and adaptive immune system. (Holleran, et al., 2017)

Our Immunotherapy R&D Services

At Ace Therapeutics, we're the global leader in research into IBD. As a preclinical contract research provider for immune-regulating therapy R&D, we support competitive pharmaceutical and biotechnology companies seeking innovative breakthroughs leading to development of new therapeutics for IBD. Leading the frontiers of natural immune system biology, our research and development specialists provide immunology and gut biology, and drug discovery.

At Ace Therapeutics, we offer a comprehensive service for immunology research all the way to immunotherapy development for IBD.

Analysis of the Immune Mechanisms in the Pathogenesis of IBD

We support our clients in exploring the role of the innate and adaptive immune system in IBD pathogenesis. It is a central point in our understanding of the overlap in the interactions between the innate and adaptive immune systems that can guide us towards novel avenues of discovery on the immunological mechanisms of intestinal inflammation.

Analysis of the Innate Immune System in IBD

• Profiling of immune cells. We can assess the activity and functions of innate immune cells, including macrophages, dendritic and natural killer cells, and their role in intestinal inflammation.
• Cytokine and chemokine assay. For clients who would like to investigate the molecular mechanisms of upregulation of cytokines (e.g., IL-1β, TNF-α, IL-6) and chemokines in intestinal inflammation and the consequences to the immune response, we provide a quantification of several cytokines and chemokines.
• Intestinal barrier function. Our assessment helps clients evaluate changes in intestinal barrier function and the role of the immune system within intestinal epithelial cells in maintaining integrity.

Analysis of the Adaptive Immune System in IBD

• T-cell analysis. We examine the percentage and activity of particular T cells (such as Th1, Th2, Th17 and regulatory T-cells) in IBD.
• Assessment of the B cell response. B cells also function to create memory against infections. We can analyse B cell function in IBD.
• Analysis of the autoimmune response. Understanding the underlying mechanisms of immune responses to gut microbes generated by the adaptive immune system may also provide insights into their contribution to IBD.

Immunotherapy Development Services for IBD

Understanding the underlying molecular pathophysiology of immune based gastrointestinal inflammation in IBD guides us to our clients in identifying the innate and adaptive immune systems as potential targets for biologic therapies for IBD. We also explore and conduct preclinical proof of principle safety and efficacy tests for certain immunotherapies for IBD.

Ace Therapeutics is committed to provide you all high-quality experimental data and analytical report to facilitate your immunotherapy development and accelerate the IBD drug development and short-in-time market. If you have any inquiry for our services, please feel free to contact us.